MOUNTAIN VIEW, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Pharsight
Corporation (Nasdaq: PHST), a leading provider of software and strategic
services for optimizing clinical drug development, today announced that a
top Japanese-based pharmaceutical company has purchased a clinical data
management and reporting solution including Pharsight(R) Knowledgebase
Server(TM) (PKS(TM)), WinNonlin(R) AutoPilot(TM), and PKS Reporter(TM).
This sale marks the first sale of an enterprise solution through
Pharsight's Japanese distributor CTC Laboratory Systems and the fourth new
customer for WinNonlin AutoPilot since the product's release in June of
last year. This new agreement brings Pharsight's total number of PKS
customers to 22 and is the fourth sale to a Japanese Top 50 pharmaceutical
firm.

By integrating PKS, WinNonlin AutoPilot, and PKS Reporter into one PK
data management and reporting solution, customers benefit from the power of
standardized and regulatory-compliant data handling and the efficiency of
automation of common or repetitive tasks during clinical pharmacokinetic
(PK) analysis. By using WinNonlin AutoPilot to create report-ready tables
and graphs and PKS Reporter to finalize reports and to manage report
updates, companies can vastly increase their productivity while improving
the quality and consistency of analyses and reports.

"This purchase illustrates the success of our Japanese partners from
CTC. It also demonstrates the need for global drug development
organizations to achieve higher productivity and regulatory-compliant PK
workflows that are enabled by our innovative tools," said Shawn O'Connor,
president, chief executive officer and chairman of Pharsight. "The
flexibility of PKS and AutoPilot allows clients to configure their solution
to meet the needs of their PK analysis workflow and to efficiently produce
the type of reports mandated by regulatory authorities. The potential
productivity gains from automating this work are large, with the ability to
reduce the labor required to generate these outputs by 80% in some cases.
We believe clients will continue to invest in our market-leading software
products because they offer a tangible return on investment as well as a
proven pathway to more efficient drug development."

About PKS

The Pharsight Knowledgebase Server (PKS) is a high productivity,
regulatory-compliant enterprise data management system. PKS is now
installed in over 20 major pharmaceutical and biotechnology companies and
also at FDA in connection with an extensive Pharsight FDA Cooperative
Research and Development Agreement. PKS enables pharmaceutical and
biopharmaceutical companies to better manage and control preclinical and
clinical kinetic and dynamic data and analyses. Companies use PKS to build
pharmacokinetic and pharmacodynamic (PK/PD) data management architecture
compliant with FDA regulation 21 CFR Part 11, which has set new standards
for computer system validation and usage. The PKS software is designed to
complement Pharsight's modeling and simulation technology for
computer-based drug disease modeling and clinical trial simulation. PKS
supports analysis in leading tools such as WinNonlin(R), NONMEM(R), and
SAS(R) as well as connectivity to LIMS such as Watson LIMS.

About WinNonlin AutoPilot

WinNonlin AutoPilot orchestrates PK analyses by selecting input data
from a user's local file system or PKS, and then directs WinNonlin(R) to
perform analyses and produce report quality tables, figures, and text
output (e.g., in Microsoft (R) Excel, SigmaPlot(R), and Microsoft(R) Word)
for regulatory submissions and interim reports. Formatted PK analyses
outputs must reflect the requirements and SOPs of each research
organization, and WinNonlin AutoPilot provides a user interface that allows
extensive configuration of formatting and business rules to enable clear
communication of standards and immediate use across the organization. PK
analyses that can be automated include noncompartmental analysis for
different study designs and inferential statistics (e.g., bioequivalence
testing), as well as comparisons between analytes, dose routes or other
conditions.

Used in conjunction with PKS and PKS Reporter(TM), WinNonlin AutoPilot
provides standardized, regulatory compliant, secure and automatic
generation of routine analyses and reports. Used independently of PKS and
PKS Reporter, WinNonlin AutoPilot can provide significant return on
investment through productivity gains and quality improvements in PK
analysis and reporting.

About PKS Reporter

PKS Reporter addresses the need for streamlined, systematic, and
automated report generation and signature. Using the Pharsight
Knowledgebase Server (PKS) as an underlying source of secure,
regulatory-compliant report content, PKS Reporter allows researchers to use
familiar tools such as WinNonlin and Microsoft Word(R) to construct,
update, review and approve any type of report. PKS Reporter is directly
integrated with PKS, as both a source of report content and a secure
repository for report storage and version control. PKS Reporter links
reports in Microsoft Word directly to PKS, where it draws report content
from data and modeling results created in WinNonlin Enterprise, NONMEM, SAS
and other industry-standard modeling and analysis tools. From within
Microsoft Word, researchers can browse the PKS database, loading objects
and values drawn from various PKS studies and analysis scenarios. When the
source data change, PKS Reporter marks its content as out of date, ready
for automatic update. QA staff can automate the verification of report data
by simply opening the document and selecting to have all references
checked. Users can create standardized report templates specifying report
layout, formatting and specific content elements. Report signoff is smooth
and automatically tracked with Reporter's signature tool and email
notification.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and
services that enable pharmaceutical and biotechnology companies to achieve
significant and enduring improvements in the development and use of
therapeutic products. The company's goal is to help customers reduce the
time, cost and risk of drug development, as well as optimize the post
approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug
development success: strong decision making. By adopting the Pharsight
approach, customers acquire a new decision-making process with the
potential to systematically improve every level and phase of their business
and scientific processes. Pharsight Corporation is headquartered in
Mountain View, California. Information about Pharsight is available at
http://www.pharsight.com.

Forward Looking Statements

The statements in this press release related to the performance of
Pharsight products are forward looking statements. Forward looking
statements are inherently speculative, and actual results may differ
materially from Pharsight's expectations due to a variety of factors,
including: changes in FDA regulations may affect the demand for the
product. and customers may not perceive the benefits of the product to be
the same as Pharsight believes them to be. Other risk factors relating to
Pharsight are disclosed in the company's most recent Form 10Q filed with
the Securities and Exchange Commission on November 9, 2007. All forward
looking statements are based on information available to the company on the
date hereof, and the company assumes no obligation to update such
statements.

(Date:10/12/2017)... (PRWEB) , ... October 12, ... ... ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed for ... complexity. Named in honor of pioneering researcher Rosalind Franklin, who made a ...

(Date:10/11/2017)... USA (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s ... take place on 7th and 8th June 2018 in San Francisco, CA. The Summit ... as well as several distinguished CEOs, board directors and government officials from around the ...

(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...